Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and safety.

In this GEN webinar, Qirui Fan, PhD, will explore WuXi XDC’s proprietary conjugation and payload-linker technology platform—a cutting-edge solution designed to overcome key challenges in ADC development. Discover how this platform enables the rational design of next-generation ADCs with enhanced therapeutic potential, offering greater precision, durability, and potential clinical benefits. During the webinar, you’ll learn:

• Conjugation Technologies Landscape: Gain a strategic overview of current conjugation technologies and learn how to select the optimal approach to advance your ADC program.
• Novel Conjugation Technology Platform: WuXiDARx^TM & Beyond. Explore WuXiDARx^TM, featuring clinically validated conjugation sites, improved homogeneity, flexible DARs, and simple CMC process, and other proprietary conjugation technologies.
• Next-Generation Payload-Linker Innovations: Discover novel payload-linker technologies from WuXi XDC and partners, designed to improve efficacy and/or tolerability, as well as alternative payload release mechanism for next-gen ADCs.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.